Episode Details
Back to Episodes
Feb 27, 2026 | CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3
Published 4 months, 3 weeks ago
Description
Novo's CagriSema misses non-inferiority against Zepbound in REDEFINE 4 — approval path intact,differentiation argument shifts to outcomes data. GSK pays $950M for HS235 (35Pharma), a Phase 1 activin inhibitor targeting Merck's Winrevair territory.Lilly's ACHIEVE-3 puts orforglipron decisively ahead of oral semaglutide: 31.4% of patients to near-normal A1C vs 11.7%. Two FDA decisions today: TransCon CNP for achondroplasia and Dupixent's AFRS label expansion.